EMEA-000876-PIP05-15-M05

Table of contents

Key facts

Invented name
Soliris
Active substance
Eculizumab
Therapeutic area
Neurology
Decision number
P/0074/2022
PIP number
EMEA-000876-PIP05-15-M05
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of myasthenia gravis
Route(s) of administration
Intravenous use
Contact for public enquiries
Alexion Europe SAS

Tel. +33  147100615

E-mail: pip.enquiries.eu@alexion.com

Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-000876-PIP05-15-M05
Compliance opinion date
14/10/2022
Compliance outcome
positive

Decision

Related content

How useful was this page?

Add your rating